» Articles » PMID: 24098779

The Correlation of Hippocampal T2-mapping with Neuropsychology Test in Patients with Alzheimer's Disease

Overview
Journal PLoS One
Date 2013 Oct 8
PMID 24098779
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: 1) To deduce T2, the inverse of the transverse relaxation rate (R2), in the hippocampus of healthy adults; 2) to investigate the brain iron deposition in Alzheimer's disease (AD) patients and age-matched healthy controls using T2-values.

Methods: T2-weighted data from the bilateral-hippocampi of ten AD patients and sixty healthy controls were collected at six echo time points using multi-slice multi-echo turbo spin echo (MSME-TSE) imaging on a 3.0 T MR-scanner, followed by the neuropsychological testing. The correlations between T2-values and Mini-Mental State Examination (MMSE) scores were investigated on group-wise basis (covariates in the group-wise analyses: gender, age, side and healthy/AD).

Results: There were no significant differences in hippocampal T2-values on intra-gender and inter-gender basis (P > 0.05). Hippocampal T2-values of both sides were similar (right: 85.2±2.4 milliseconds; left: 85.3±2.5 milliseconds). The bilateral hippocampal T2 values correlated moderately with age (right: r = -0.59; left: -0.58; P < 0.001). The AD-group had significantly lower T2-values in the hippocampus when compared to normal controls (P < 0.001) and such low T2-values had a strong positive correlation with the MMSE score (R (2) = 0.97; P < 0.05).

Conclusion: Patients with AD showed significantly lower T2 values, which can be attributed to the increased iron depositions in the hippocampus. A positive correlation between T2-values and cognition scores suggests that quantitative T2 can be used in the early diagnosis of AD and in the monitoring of the treatment response.

Citing Articles

Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia.

Delaby C, Alcolea D, Busto G, Gabelle A, Ayrignac X, Bennys K Alzheimers Res Ther. 2025; 17(1):42.

PMID: 39948603 PMC: 11823057. DOI: 10.1186/s13195-025-01696-9.


T1 and FLAIR signal intensities are related to tau pathology in dominantly inherited Alzheimer disease.

Rahmani F, Brier M, Gordon B, McKay N, Flores S, Keefe S Hum Brain Mapp. 2023; 44(18):6375-6387.

PMID: 37867465 PMC: 10681640. DOI: 10.1002/hbm.26514.


Constructing a prognostic risk model for Alzheimer's disease based on ferroptosis.

Wang X, Zhai R, Li Z, Li H, Lei Y, Zhao F Front Aging Neurosci. 2023; 15:1168840.

PMID: 37181620 PMC: 10172508. DOI: 10.3389/fnagi.2023.1168840.


Phase-based fast 3D high-resolution quantitative T MRI in 7 T human brain imaging.

Seginer A, Schmidt R Sci Rep. 2022; 12(1):14088.

PMID: 35982143 PMC: 9388657. DOI: 10.1038/s41598-022-17607-z.


The cognitive dysfunction related to Alzheimer disease or cerebral small vessel disease: What's the differences.

Liang Z, Wu L, Gong S, Liu X Medicine (Baltimore). 2021; 100(34):e26967.

PMID: 34449462 PMC: 8389965. DOI: 10.1097/MD.0000000000026967.


References
1.
Schenck J, Zimmerman E, Li Z, Adak S, Saha A, Tandon R . High-field magnetic resonance imaging of brain iron in Alzheimer disease. Top Magn Reson Imaging. 2006; 17(1):41-50. DOI: 10.1097/01.rmr.0000245455.59912.40. View

2.
Thompson C, Markesbery W, Ehmann W, Mao Y, Vance D . Regional brain trace-element studies in Alzheimer's disease. Neurotoxicology. 1988; 9(1):1-7. View

3.
Liu G, Garrett M, Men P, Zhu X, Perry G, Smith M . Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta. 2005; 1741(3):246-52. DOI: 10.1016/j.bbadis.2005.06.006. View

4.
Giannakopoulos P, Hof P, Giannakopoulos A, Herrmann F, Michel J, Bouras C . Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of very old patients. Arch Neurol. 1995; 52(12):1150-9. DOI: 10.1001/archneur.1995.00540360028012. View

5.
Zheng H, Weiner L, Bar-Am O, Epsztejn S, Cabantchik Z, Warshawsky A . Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem. 2005; 13(3):773-83. DOI: 10.1016/j.bmc.2004.10.037. View